Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Liabilities (2020 - 2026)

Cytek Biosciences filings provide 6 years of Total Liabilities readings, the most recent being $119.8 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 15.46% to $119.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $119.8 million, a 15.46% increase, with the full-year FY2025 number at $119.8 million, up 15.46% from a year prior.
  • Total Liabilities hit $119.8 million in Q4 2025 for Cytek Biosciences, up from $116.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $119.8 million in Q4 2025 to a low of -$1.1 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $100.2 million (2023), compared with a mean of $87.9 million.
  • Biggest five-year swings in Total Liabilities: soared 7230.64% in 2022 and later dropped 6.22% in 2024.
  • Cytek Biosciences' Total Liabilities stood at $57.9 million in 2021, then soared by 62.17% to $93.9 million in 2022, then increased by 7.95% to $101.4 million in 2023, then grew by 2.34% to $103.8 million in 2024, then rose by 15.46% to $119.8 million in 2025.
  • The last three reported values for Total Liabilities were $119.8 million (Q4 2025), $116.3 million (Q3 2025), and $115.8 million (Q2 2025) per Business Quant data.